Top of this page
Skip navigation, go straight to the content


A new pre-and post-synaptic inhibitor (PPSI) drug candidate, UCB0942, with an innovative mechanism of action has been designed for the treatment of pharmacoresistant epilepsy.

Expected indication pharmacoresistant epilepsy
R&D stage Phase 1 ongoing (started in december 2010)
Next milestone Phase 1 results

Quick facts on epilepsy